Lead Manager on Praxis Precision Medicines’ $603.8MM Confidentially Marketed Public Offering

Oppenheimer & Co. Inc. acted as Lead Manager on Praxis Precision Medicines’ $603.8MM Confidentially Marketed Public Offering

Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, announced the closing of its underwritten public offering of 3,025,480 shares of its common stock at a public offering price per share of $157.00 and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 318,470 shares of common stock at a purchase price of $156.9999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The underwriters exercised a 30-day option to purchase up to 501,592 additional shares of common stock at the public offering price, less underwriting discounts and commissions, bringing the gross proceeds of the offering to approximately $603.8 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis. All shares and pre-funded warrants in the offering are being offered by Praxis.

Healthcare Life Science Investment Banking